Last reviewed · How we verify
Camrelizumab+Apatinib+Eribulin
This combination therapy enhances anti-tumor immunity by blocking PD-1 checkpoint inhibition while simultaneously inhibiting angiogenesis and disrupting microtubule dynamics to suppress tumor growth.
This combination therapy enhances anti-tumor immunity by blocking PD-1 checkpoint inhibition while simultaneously inhibiting angiogenesis and disrupting microtubule dynamics to suppress tumor growth. Used for Advanced or metastatic breast cancer (phase 3 investigation).
At a glance
| Generic name | Camrelizumab+Apatinib+Eribulin |
|---|---|
| Sponsor | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
| Drug class | PD-1 inhibitor + tyrosine kinase inhibitor + microtubule inhibitor combination |
| Target | PD-1 (camrelizumab), VEGFR-2 (apatinib), microtubule dynamics (eribulin) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Camrelizumab is a PD-1 inhibitor that restores T-cell-mediated anti-tumor immunity by blocking the PD-1/PD-L1 axis. Apatinib is a tyrosine kinase inhibitor targeting VEGFR-2 that suppresses tumor angiogenesis and vascular endothelial growth. Eribulin is a microtubule dynamics inhibitor that disrupts mitotic spindle formation and induces apoptosis in cancer cells. The triple combination aims to synergistically attack tumors through immune activation, anti-angiogenesis, and direct cytotoxicity.
Approved indications
- Advanced or metastatic breast cancer (phase 3 investigation)
Common side effects
- Immune-related adverse events (fatigue, rash, hepatotoxicity)
- Hypertension
- Peripheral neuropathy
- Neutropenia
- Anemia
Key clinical trials
- Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer (PHASE3)
- A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: